Oxford Instruments plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OXINF research report →
Price Chart
About the company
Oxford Instruments plc provide scientific technology products and services for academic and commercial organizations in the United Kingdom and internationally. It operates through two segments: Imaging and Analysis and Advanced Technologies. The company offers atomic force, electron, light, and Raman microscopy; deposition tools comprising plasma enhanced chemical vapour deposition, inductively coupled plasma chemical vapour deposition, atomic layer deposition, and ion beam deposition systems; and etch tools, including inductively coupled plasma etching, reactive ion etching, deep silicon etching, atomic layer etching, and ion beam etching systems.
- CEO
- John Richard Tyson
- IPO
- 2011
- Employees
- 2,117
- HQ
- High Wycombe, BU, GB
Get TickerSpark's AI analysis on OXINF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.09B
- P/E
- 32.21
- Fwd P/E
- 33.65
- PEG
- 0.34
- P/S
- 3.60
- P/B
- 4.51
- EV/EBITDA
- 17.31
- Div Yield
- 0.85%
- Gross Margin
- 53.95%
- Op Margin
- 15.93%
- Net Margin
- 11.39%
- ROE
- 13.94%
- ROIC
- 12.87%
Latest fiscal year · YoY change
- Revenue
- $424.28M-15.2%
- Gross Profit
- $228.88M-11.6%
- Op Income
- $63.86M
- Net Income
- $48.32M+85.9%
- EPS
- $0.85+88.9%
- OCF Growth
- +11.9%
- FCF Growth
- +43.1%
- 52W High
- $45.90
- 52W Low
- $23.70
- 50D MA
- $40.14
- 200D MA
- $33.79
- Beta
- 1.11
- RSI (14)
- 28
- Avg Volume
- 247
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Oxford Instruments finished FY26 with stronger second-half orders, improved margins, and a much larger Advanced Technologies order book that supports confidence in FY27 growth.· June 9, 2026
- Full-year order intake rose 8% on an organic constant-currency basis, with H2 up 14%; revenue declined 3% as order timing lagged shipments.
- Imaging and Analysis recovered through the year, with FY26 orders up 1.9% and revenue down 3%, but margin improved on Belfast restructuring and efficiency gains.
- Advanced Technologies was the growth engine: FY26 orders rose 28%, the order book ended 25% higher than the start of the year, and management expects high-teens revenue growth in FY27.
- Group adjusted operating margin improved by 30 basis points on a constant-currency basis; cash conversion stayed strong at 89%.
- Capital allocation remains growth-focused: the company plans an additional GBP 10 million of investment in FY27, will raise the dividend by 6.3%, and is continuing a GBP 100 million buyback program.
On an organic constant-currency basis, full-year order intake finished up 8% and was up 14% in the second half. Revenue declined 3% for the year, driven by order-to-revenue timing, while group margin improved by 30 basis points on a constant-currency basis. Cash conversion was 89%, and free cash flow remained robust. In Imaging and Analysis, full-year order intake was up 1.9% and revenue was down 3%; in Advanced Technologies, order intake rose 28% and revenue was slightly down for the year due to Q4 timing. Looking ahead, management expects Imaging and Analysis to deliver low single-digit revenue growth in FY27 and Advanced Technologies to deliver high-teens revenue growth, with further margin progress despite a GBP 3.2 million FX headwind in FY27.
Richard Tyson framed FY26 as a year of meaningful strategic progress after a difficult start, saying the business is now “very different” from 2023 and is simpler, more commercially focused, and better positioned. He highlighted the shift toward high-volume manufacturing customers, stronger customer intimacy, better service revenue, and the benefits of restructuring and portfolio refocusing, including the NanoScience divestment. His tone was upbeat and confident, with repeated emphasis that the company is in “really good shape” for FY27 and beyond.
Paul Fry emphasized the financial turnaround in the second half: order intake recovered progressively, gross margin improved through Belfast restructuring and operational excellence, and constant-currency operating margin rose 30 basis points. He said cash conversion remained 89% and free cash flow was supported by lower cash tax from prior overpayments and Yatton sale proceeds; even without those items recurring, he expects free cash flow to improve as adjusting items fall and pension contributions have ceased. He also noted a FY27 FX headwind of around GBP 3.2 million, a tax rate stabilizing around 24.5%, an additional GBP 10 million of investment in growth opportunities, a 6.3% dividend increase, and completion of the GBP 100 million buyback program by year-end.
Analysts focused on Advanced Technologies visibility, lead times, and whether the big April order was a one-off. Management said the large orders reflect multiple customers ramping production, not a single isolated event, and that the business is working to add labor capacity and reduce lead times, with current order book and service revenue materially covering FY27. Questions also probed semiconductors in Imaging and Analysis, pricing power in AT, and the mix of datacom versus other compound-semi applications; management said semis are increasingly relevant in I&A through cross-sell and product/software integration, and in AT datacom is growing very quickly but does not dominate the order book, which remains diversified across GaN, augmented reality, quantum, and academia.
The call showed a clear second-half recovery, especially in orders, margin, and execution, with Advanced Technologies emerging as a strong growth platform. Management sounded confident that FY27 is already well covered and that revenue and margin should continue to improve as new capacity, product investments, and a more focused customer strategy take hold.
The main risks are execution and mix: FY26 revenue lagged orders, Q4 was lumpy, and management said large AT systems can create quarter-to-quarter volatility. Headwinds remain in U.S. academia funding, FX, and the need to keep improving lead times and capacity as the company shifts more toward complex production customers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.9%
- Shares Outstanding
- 54.99M
- Float Shares
- 53.26M
Our OXINF coverage
Recent articles, reports, and earnings notes.
No research on OXINF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OXINF report →Oxford Instruments plc (OXINF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Jun 11
Oxford Instruments H2 Earnings Call Highlights
marketbeat.com · Jun 9
Oxford Instruments falls on profits dip despite order boost from semiconductors
proactiveinvestors.co.uk · Jun 9
Oxford Instruments (OTCMKTS:OXINF) Shares Gap Down – Here’s What Happened
defenseworld.net · Jan 11
Oxford Instruments plc (OXINF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
Oxford Instruments buoyed by recovering orders and cost discipline
proactiveinvestors.co.uk · Nov 11
Oxford Instruments shares slide 14% as tariffs weigh on first-half sales
proactiveinvestors.co.uk · Oct 13
Oxford Instruments sells quantum business for £60m
proactiveinvestors.co.uk · Jun 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.